{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:14:22Z","timestamp":1788668062542,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.blre.2026.101409","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:16:11Z","timestamp":1780586171000},"page":"101409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting CD38 in immune thrombocytopenia: Rationale and a scoping review of daratumumab"],"prefix":"10.1016","volume":"77","author":[{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Abdullah","family":"Dalol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen Haj","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba Adel","family":"Aweer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101409_bb0005","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/hematology.2024000594","article-title":"Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy","volume":"2024","author":"Ghanima","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2026.101409_bb0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/hematology.2025000720","article-title":"Refractory ITP: revisiting definitions, diagnostics, and management paradigms","volume":"2025","author":"Panch","year":"2025","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2026.101409_bb0015","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101409_bb0020","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101409_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1519300","article-title":"Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects","volume":"16","author":"Horenstein","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101409_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103849","article-title":"Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial","volume":"94","author":"Chen","year":"2026","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.blre.2026.101409_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2025017279","article-title":"Safety and efficacy of daratumumab in immune thrombocytopenia","volume":"10","author":"Tsykunova","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101409_bb0040","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1056\/NEJMoa2513120","article-title":"A phase 2 randomized trial of Mezagitamab in primary immune thrombocytopenia","volume":"394","author":"Kuter","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101409_bb0045","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1182\/blood-2025-4818","article-title":"Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections","volume":"146","author":"Han","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101409_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153580","article-title":"High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura","volume":"132","author":"Canales-Herrerias","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101409_bb0055","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/bloodadvances.2020003860","article-title":"Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia","volume":"5","author":"Yu","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101409_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101409_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103289","article-title":"The potential of CD38 protein as a target for autoimmune diseases","volume":"22","author":"Ye","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2026.101409_bb0070","doi-asserted-by":"crossref","first-page":"20332","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2026.101409_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory effects of CD38-targeting antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.blre.2026.101409_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084314","article-title":"Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial","volume":"391","author":"Chen","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2026.101409_bb0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood-2013-04-490821","article-title":"Inhibitory Fc\u03b3RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity","volume":"123","author":"Vaughan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101409_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145342","article-title":"Novel markers to delineate murine M1 and M2 macrophages","volume":"10","author":"Jablonski","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2026.101409_bb0095","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2026.101409_bb0100","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16171","article-title":"Post-allogeneic transplant Evans syndrome successfully treated with daratumumab","volume":"187","author":"Blennerhassett","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101409_bb0105","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematol"},{"key":"10.1016\/j.blre.2026.101409_bb0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/JBM.S468921","article-title":"Successful treatment of steroid-refractory immune thrombocytopenia in a patient developing multiple myeloma while on immune checkpoint inhibitor therapy for lung cancer: a case report","volume":"15","author":"Hayashi","year":"2024","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2026.101409_bb0115","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ajh.70148","article-title":"Daratumumab in pediatric chronic refractory primary immune thrombocytopenia (ITP): rapid platelet recovery, sustained response, and immune reconstitution dynamics","volume":"101","author":"Hu","year":"2026","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101409_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1625365","article-title":"Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review","volume":"16","author":"Jing","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101409_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.70102","article-title":"Bloodless management of severe refractory ITP and acute hemorrhage in a Jehovah\u2019s witness patient","volume":"13","author":"Kaur","year":"2025","journal-title":"Clin Case Reports"},{"key":"10.1016\/j.blre.2026.101409_bb0130","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/bjh.17565","article-title":"Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series","volume":"194","author":"Khandelwal","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101409_bb0135","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2025-3032","article-title":"Long-term remissions in refractory ITP patients by daratumumab","volume":"146","author":"List","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101409_bb0140","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-116560","article-title":"A case report of refractory immune thrombocytopenia (ITP) following reduced intensity conditioning (RIC) hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) successfully treated with off-label use of Daratumumab","volume":"132","author":"Migdady","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101409_bb0145","article-title":"Unveiling daratumumab\u2019s efficacy in refractory ITP: a post-allogeneic HSCT triumph in AML-MRC","volume":"25","author":"Peshin","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101409_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30472","article-title":"Successful sequential therapy with rituximab and daratumumab for refractory posttransplant immune thrombocytopenic purpura","volume":"70","author":"Shino","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101409_bb0155","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/bjh.19660","article-title":"Long-term complete remissions of refractory severe idiopathic immune thrombocytopenia treated with daratumumab: a case series","volume":"205","author":"Str\u00fc\u00dfmann","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101409_bb0160","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMc2501527","article-title":"Daratumumab in relapsed or refractory pediatric immune thrombocytopenia","volume":"392","author":"Sun","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101409_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2026.101409_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S487895","article-title":"Daratumumab and Romiplostim combined therapy for a long-standing refractory primary immune thrombocytopenia - case report","volume":"14","author":"Zoubi","year":"2025","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.blre.2026.101409_bb0175","doi-asserted-by":"crossref","unstructured":"Huang Z-Y, Liu X-L, Li T, Luo C-H. Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis. Front Oncol n.d.;15:1729177. Doi: https:\/\/doi.org\/10.3389\/fonc.2025.1729177.","DOI":"10.3389\/fonc.2025.1729177"},{"key":"10.1016\/j.blre.2026.101409_bb0180","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2012-07-442392","article-title":"Standardization of bleeding assessment in immune thrombocytopenia: report from the international working group","volume":"121","author":"Rodeghiero","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101409_bb0185","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101409_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.blre.2026.101409_bb0195","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(25)02515-2","article-title":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia","volume":"407","author":"Duque-Afonso","year":"2026","journal-title":"Lancet"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:59:52Z","timestamp":1788667192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S0268960X26000482"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101409","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CD38 in immune thrombocytopenia: Rationale and a scoping review of daratumumab","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101409"}}